Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

Status unconfirmed · Phase 2/Phase 3

Conditions studied: Stuttering, Adult, Childhood-onset Fluency Disorder, Speech Disorders, Language Disorders, Communication Disorder

In brief

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms. It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.

Key facts

Study ID

NCT02909088

Run by

Gerald Maguire, MD

People needed

10

Starts

2016-09-01

Expected to finish

2017-11-01

Last updated by the study team

2016-10-26

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects can be enrolled in the study only if they meet all of the following criteria:
• Subjects must satisfy DSM-IV criteria for childhood onset fluency disorder (stuttering).
• The nature of stuttering must be developmental in origin with the onset prior to ten years of age.
• Subjects must have a score of moderate or higher on the SSI-IV.
• Women of child-bearing potential are eligible to participate as long as they are practicing a medically accepted form of contraception (i.e. condom with spermicide or diaphragm, oral or depot contraception, or an intrauterine device).
• Subjects will be male or female from the ages of 18-60.
• Subject must have a MADRS total score of ≤ 13 (normal mood)
• Subjects will be of only English speaking.

You may not qualify if…

• Subjects will be excluded from the study for any of the following reasons:
• Adult individuals who lack capacity to consent for themselves.
• Stuttering related to a known neurologic cause (e.g. head trauma, stroke).
• Unstable medical or psychiatric illness.
• Active substance abuse within three months prior to study inclusion.
• Any illness that would require the concomitant use of a CNS active medication during the course of the study.
• Subjects with Parkinson's dementia or other degenerative neurologic illness.
• Suffer from irregular heart rate or seizures
• Subjects who are pregnant or nursing an infant.
• Subject with a MADRS ≥ 14
• Breastfeeding a child during the course of the study or for one month following completion
• It is the investigator's opinion that the subject poses a significant suicide risk by the following criteria:
• It is the investigator's opinion that the subject may be at risk of suicide.
• the subject responds "yes" to question #4 (Active Suicidal Ideation with Specific Plan and Intent) on the Baseline Visit of the Columbia Suicide Severity Rating Scale (C-SSRS), if the most recent episode occurred within the past 12 months.

Where it is running

• CITrials — Riverside, California, United States (enrolling)
• University of California Riverside School of Medicine — Riverside, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.